Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

STK11 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	nivolumab Resistant: B - Late Trials nivolumab Resistant : B	nivolumab Resistant: B - Late Trials nivolumab Resistant : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	durvalumab Resistant: B - Late Trials durvalumab Resistant : B	durvalumab Resistant: B - Late Trials durvalumab Resistant : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	Sensitive: B - Late Trials Sensitive : B	Sensitive: B - Late Trials Sensitive : B
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B
STK11 mutation	Solid Tumor	STK11 mutation	Solid Tumor	TNG260 Sensitive: C2 – Inclusion Criteria TNG260 Sensitive : C2	TNG260 Sensitive: C2 – Inclusion Criteria TNG260 Sensitive : C2
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3